ArticleTrends in pharmacological sciences2011
Treating brain tumors with PDE4 inhibitors.
Article in Trends in pharmacological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Serum Proteomic Analysis Using Gel-Based Liquid Chromatography Tandem Mass Spectrometry Reveals Differences Between Canine Oral Malignancies and Non-Malignant Conditions.Veterinary medicine and science · 2026Article
- A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen.International journal of molecular sciences · 2025Review
- PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges.Frontiers in oncology · 2025Review
- Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer.Journal of Cancer · 2021Article
- Review
- Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review.Oncotarget · 2019Review
- Development of anticancer agents targeting the Hedgehog signaling.Cellular and molecular life sciences : CMLS · 2017Review
- Review
- The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis.Cell cycle (Georgetown, Tex.) · 2016Review
- Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk.Molecular & cellular oncology · 2016Article
- A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.Leukemia · 2016Article
- Review
- An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition.Cell reports · 2015Article
- Targeting brain tumor cAMP: the case for sex-specific therapeutics.Frontiers in pharmacology · 2015Article
- The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma.Nature medicine · 2014Article
- Article
- PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells.PloS one · 2014Article
- Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445).Journal of natural products · 2013Article
- Targeted activation of PKA and Epac promotes glioblastoma regressionMolecular and clinical oncology · 2013Article
- Cyclic AMP, protein kinase A, and phosphodiesterases: proceedings of an international workshop.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Speculation regarding dysregulation of cAMP metabolism in oncogenesis has existed since the discovery of cAMP more than 50 years ago. Recent data confirm the relevance of disordered cAMP metabolism to the genesis of multiple cancers and suggest that the mechanism might involve altered expression and activity of phosphodiesterases (PDEs). These discoveries coincide with the rapid development and clinical evaluation of PDE inhibitors for non-cancer indications. Thus, the time is ripe to evaluate PDE inhibitors as cancer chemotherapeutics. Here we highlight recent evidence that abnormal regulation of cAMP levels might be a determinant of brain tumorigenesis and that altered PDE expression is one the mechanisms of its dysregulation. Recent preclinical and clinical experience with inhibitors of PDE4 indicates that this might be a promising approach to brain tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.